Just caught an interesting development in the biotech space. Serina Therapeutics just dosed their first patient in a Phase 1b trial for SER-252, an investigational apomorphine therapy targeting advanced Parkinson's disease. This is actually pretty significant because the FDA already gave them the green light on the IND application back in January.

What makes this noteworthy is the regulatory pathway they've secured. The FDA has aligned with Serina on a 505(b)(2) NDA route and recognized their Phase 1b trial as registrational. That's basically saying the clinical data from this trial could potentially be used directly for market approval, which is a more efficient path than the traditional approach. CEO Steve Ledger highlighted that this FDA alignment positions them to generate the necessary clinical data more efficiently.

So what's SER-252 actually doing? It's built on their POZ platform and designed to deliver continuous dopaminergic stimulation in Parkinson's patients. The idea is to reduce levodopa-related motor complications like dyskinesia, which is a real problem for advanced patients whose current treatments aren't cutting it anymore.

The trial itself is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced Parkinson's where standard therapies aren't adequately controlling symptoms. They're working with Parkinson's Australia and Neuroscience Trials Australia on patient enrollment, and they're expecting the blinded safety review from Cohort 1 to clear the way for Cohort 2 advancement sometime in Q3 this year.

Beyond SER-252, Serina's pipeline is pretty interesting too. They've got SER-214 for early Parkinson's and Restless Leg Syndrome that already completed Phase 1a, and SER-270 (a VMAT2 inhibitor long-acting injectable) in development for movement disorders and Tardive Dyskinesia. The POZ platform itself has broader applications across small molecules, RNA therapeutics, and ADCs, so there's potential upside beyond just this one program.

Given that over 10 million people globally have Parkinson's disease, there's clearly a significant market need here. Interesting to watch how this trial progresses through the rest of 2026.